Imfinzi 500mg Injection Abu Dhabi | Top Pharma Exporter from India

Imfinzi 500mg Injection: Breakthrough PD-L1 Immunotherapy for Advanced Solid Tumors

Are you searching for a reliable Imfinzi 500 mg injection exporter from India? Ernest Oncology, a specialized division of Ernest Pharmaceutical Pvt. Ltd., is a premier global supplier and bulk distributor of advanced immunotherapy. We serve high-demand healthcare markets in the UK (London), USA, UAE (Abu Dhabi), Australia, and South Africa, facilitating the international supply of life-saving biologics through a secure, cold-chain pharmaceutical network.

Detailed Product Overview: What is Imfinzi 500mg?

Imfinzi 500 mg is a high-potency sterile solution containing the active monoclonal antibody Durvalumab. It is a human immunoglobulin G1 kappa (IgG1κ) monoclonal antibody that blocks the interaction of programmed cell death ligand-1 (PD-L1) with PD-1 and CD80.

By targeting the PD-L1 pathway, Imfinzi restores the ability of the patient's immune system to detect and destroy cancer cells. It is recognized globally as a foundational treatment for several aggressive malignancies, particularly in the lungs and biliary tract.

Primary Therapeutic Indications: 

Imfinzi 500 mg is clinically indicated for:

• Non-Small Cell Lung Cancer (NSCLC): For adult patients whose unresectable Stage III NSCLC has not progressed following concurrent platinum-based chemotherapy and radiation therapy.

• Small Cell Lung Cancer (SCLC): In combination with chemotherapy (etoposide and either carboplatin or cisplatin) as a first-line treatment for adult patients with extensive-stage SCLC.

• Biliary Tract Cancer (BTC): In combination with gemcitabine and cisplatin for the treatment of locally advanced or metastatic BTC.

• Hepatocellular Carcinoma (HCC): Used in combination with Tremelimumab for adult patients with unresectable HCC.

Mechanism of Action: How Imfinzi 500 mg Works:

Imfinzi is an "Immune Checkpoint Inhibitor" that targets the PD-L1 protein.

1. Checkpoint Blockade: Many cancer cells express PD-L1 on their surface. When PD-L1 binds to the PD-1 receptor on T-cells, it sends an "off" signal, preventing the immune system from attacking the tumor.

2. Tislelizumab Binding: Durvalumab (Imfinzi) binds specifically to PD-L1.

3. T-Cell Reactivation: By blocking the PD-L1/PD-1 interaction, Imfinzi "releases the brakes" on the immune system, allowing T-cells to identify, target, and kill the cancer cells.

Administration and Dosage:

• Route: Administered as an Intravenous (IV) Infusion by a qualified oncology professional.

• Vial Strength: The 500mg/10mL vial allows for accurate dosing in clinical settings.

• Schedule: Dosage varies by indication and patient weight (fixed-dose or weight-based dosing), typically administered every 2 to 4 weeks.

Clinical Side Effects & Safety Monitoring:

As an immunotherapy, Imfinzi can cause immune-mediated adverse reactions. Monitoring is required for:

• Pneumonitis: Inflammation of the lungs.

• Colitis: Inflammation of the intestines.

• Endocrinopathies: Disorders of the thyroid, adrenal glands, or pituitary gland.

• Common Symptoms: Cough, fatigue, hair loss, and nausea.

Why source Imfinzi 500 mg from Ernest Oncology?

• Advanced Cold Chain Logistics: Biologics like Imfinzi require strict temperature control (2°C to 8°C). We ensure validated thermal packaging for export to the USA, UK, UAE, Australia, and South Africa. 

• Authenticity Guaranteed: Direct procurement from GMP-certified facilities, ensuring the integrity of every export from India shipment.

• Bulk Availability: Consistent inventory management for hospital tenders and international pharmaceutical distribution.

• B2B Documentation: We provide comprehensive documentation, including Certificates of Analysis (COA) and export permits for seamless customs clearance.